ONO-7913

· Ono Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ONO-7913, covering 2024-05-03 to 2024-11-14. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer [Phase 1]

See pricing